Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 8:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Inhaled Treprostinil Therapy Clear all
Active, not recruiting Phase 2Phase 3 Interventional

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)

NCT05649748
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Palmitil, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 16, 2026, 8:40 AM EDT
Terminated Phase 2 Interventional Results available

Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

NCT00703339
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
Interventions
Treprostinil sodium for inhalation
Drug
Lead sponsor
Lung Biotechnology PBC
Industry
Eligibility
35 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
La Jolla, California • Sacramento, California • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Sep 16, 2026, 8:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalation Powder (TPIP) Formulation 2 (F2) to TPIP Formulation 3 (F3) in Healthy Participants

NCT07102316
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TPIP F2, TPIP F3
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 16, 2026, 8:40 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension

NCT02471183
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Selexipag
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
La Jolla, California • San Francisco, California • Torrance, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 16, 2026, 8:40 AM EDT
Terminated No phase listed Observational

Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching

NCT01494896
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Jacksonville, Florida • Weston, Florida
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Sep 16, 2026, 8:40 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)

NCT04791514
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Palmitil
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Sep 16, 2026, 8:40 AM EDT
Completed Phase 4 Interventional Results available

Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication

NCT01268553
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
3
States / cities
Tucson, Arizona • San Francisco, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Sep 16, 2026, 8:40 AM EDT
Completed No phase listed Observational Results available

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

NCT01266265
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin, oral ERA, oral PDE5 inhibitors
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
Not listed
Enrollment
1,333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
88
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2016 · Synced Sep 16, 2026, 8:40 AM EDT
Completed Phase 2 Interventional

Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension

NCT03814317
View directory record Official record
Conditions
Sarcoidosis, Precapillary Pulmonary Hypertension, Interstitial Lung Disease
Interventions
Inhaled Treprostinil
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 16, 2026, 8:40 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

NCT05147805
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Palmitil, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 16, 2026, 8:40 AM EDT
Completed No phase listed Observational Results available

Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH

NCT03888365
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil, Non-Treprostinil PAH Medications
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Timeline
2019
U.S. locations
10
States / cities
Birmingham, Alabama • Beverly Hills, California • Santa Barbara, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Sep 16, 2026, 8:40 AM EDT
Completed Phase 1 Interventional Results available

Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso

NCT03950739
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Inhalation Powder
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Sep 16, 2026, 8:40 AM EDT
Completed Phase 4 Interventional Results available

A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).

NCT01305252
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
treprostinil inhalations, tadalafil
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 69 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Stanford, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Sep 16, 2026, 8:40 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years

NCT02276872
View directory record Official record
Conditions
PAH
Interventions
oral treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
7 Years to 17 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
9
States / cities
Palo Alto, California • San Francisco, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 16, 2026, 8:40 AM EDT
Terminated Phase 4 Interventional

Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction

NCT00458042
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
treprostinil sodium
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
2
States / cities
La Jolla, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 11, 2007 · Synced Sep 16, 2026, 8:40 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension

NCT05564637
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Interstitial Lung Disease, Healthy Adults
Interventions
Treprostinil, Right Heart Catheterization (RHC) while exercising, Optional Muscle Biopsy
Drug · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 16, 2026, 8:40 AM EDT
Completed Phase 1 Interventional

Treatment of Pulmonary Hypertension Associated COPD With Inhaled Treprostinil-1

NCT01758744
View directory record Official record
Conditions
Pulmonary Hypertension, COPD
Interventions
Inhaled Treprostinil Therapy
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Aurora, Colorado • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Sep 16, 2026, 8:40 AM EDT
Recruiting Phase 3 Interventional

An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT07234032
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease
Interventions
Treprostinil Palmitil Inhalation Powder, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Naples, Florida • Bend, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 16, 2026, 8:40 AM EDT
Recruiting Phase 2 Interventional

Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia

NCT07037836
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease), Hypoxemia
Interventions
Inhaled Treprostinil (Tyvaso Nebulizer)
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
40 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 16, 2026, 8:40 AM EDT